,19 Given that muscle and metabolic issues are more prominent in nondermatological inflammatory conditions such as rheumatoid arthritis and myelofibrosis, patients may experience more significant weight gain when the JAK/STAT pathway is inhibited due to reduced muscle wasting. This evidence concerns the gene SOAT1 and myelofibrosis.